CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions

Carcinogenesis

Volumn 28, Issue 12, 2007, Pages 2552-2559

  Crawford, E L ^a   Blomquist, T ^a   Mullins, D N ^a   Yoon, Y ^a   Hernandez, D R ^a   Al Bagdhadi, M ^a   Ruiz, J ^a   Hammersley, J ^a   Willey, James C ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CCAAT ENHANCER BINDING PROTEIN GAMMA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 5; LUCIFERASE; MESSENGER RNA; PROTEIN DERIVATIVE; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR YY1; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ARTICLE; BRONCHUS MUCOSA; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA REPAIR; EPITHELIUM CELL; EXPRESSION VECTOR; GEL MOBILITY SHIFT ASSAY; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INDIVIDUALIZATION; LUNG CARCINOGENESIS; LUNG CARCINOMA; MOLECULAR RECOGNITION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REPORTER GENE; UPREGULATION;

BINDING SITES; BRONCHI; CCAAT-ENHANCER-BINDING PROTEINS; CELLS, CULTURED; DNA REPAIR; DNA-BINDING PROTEINS; E2F1 TRANSCRIPTION FACTOR; ENDONUCLEASES; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; RESPIRATORY MUCOSA; TRANSCRIPTION FACTORS; YY1 TRANSCRIPTION FACTOR;

EID: 36949027758     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm214     Document Type: Article

References (69)

1. Jemal,A. et al. (2002) Cancer statistics, 2002. CA Cancer J. Clin., 52, 23-47.
2. Hecht,S.S. (1999) Tobacco smoke carcinogens and lung cancer. J. Natl Cancer Inst., 91, 1194-1210.
3. Bach,P.B. et al. (2003) Variations in lung cancer risk among smokers. J. Natl Cancer Inst., 95, 470-478.
4. Khuder,S.A. (2001) Effect of cigarette smoking on major histological types of lung cancer: A meta-analysis. Lung Cancer, 31, 139-148.
5. Mattson,M.E. et al. (1987) What are the odds that smoking will kill you? Am. J. Public Health, 77, 425-431.
6. Samet,J.M. (1991) Health benefits of smoking cessation. Clin. Chest Med., 12, 669-679.
7. Halpern,M.T. et al. (1993) Patterns of absolute risk of lung cancer mortality in former smokers. J. Natl Cancer Inst., 85 457-464.
8. Lubin,J.H. et al. (1993) Lung cancer and smoking cessation: patterns of risk. J. Natl Cancer Inst., 85, 422-423.
9. Sobue,T. et al. (1993) Lung cancer incidence rate for male ex-smokers according to age at cessation of smoking. Jpn. J. Cancer Res., 84, 601-607.
10. Strauss,G.M. et al. (1997) Screening for lung cancer. Another look; a different view. Chest, 111, 754-768.
11. Tong,L. et al. (1996) Lung carcinoma in former smokers. Cancer 78, 1004-1010.
12. Greenwald,P. (1996) Cancer risk factors for selecting cohorts for largescale chemoprevention trials. J. Cell. Biochem. Suppl., 25 29-36.
13. Kelloff,G.J. et al. (1996) Risk biomarkers and current strategies for cancer chemoprevention. J. Cell. Biochem. Suppl., 25, 1-14.
14. Schwartz,A.G. et al. (2007) The molecular epidemiology of lung cancer. Carcinogenesis, 28, 507-518.
15. Baldwin,P.D. (2003) Lung cancer. Clin. J. Oncol. Nurs., 7, 699-702.
16. Schwartz,A.G. et al. (2006) Familial lung cancer: Genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 173, 16-22.
17. Berwick,M. et al. (2000) Markers of DNA repair and susceptibility to cancer in humans: An epidemiologic review. J. Natl Cancer Inst. 92, 874-897.
18. Spitz,M.R. et al. (2003) Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol. Biomarkers Prev. 12, 689-698.
19. Mohrenweiser,H.W. et al. (1998) Variation in DNA repair is a factor in cancer susceptibility: A paradigm for the promises and perils of individual and population risk estimation? Mutat. Res., 400 15-24.
20. Paz-Elizur,T. et al. (2003) DNA repair activity: For oxidative damage and risk of lung cancer. J. Natl Cancer Inst., 95, 1312-1319.
21. Cheng,L. et al. (1998) Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol. Biomarkers Prev., 7, 465-468.
22. Garcia-Closas,M. et al. (2006) Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol. Biomarkers Prev., 15, 536-542.
23. Shen,M. et al. (2006) Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum. Genet., 119, 659-668.
24. Wei,Q. et al. (1996) Reduced DNA repair capacity in lung cancer patients. Cancer Res., 56, 4103-4107.
25. Wu,X. et al. (1998) A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls. Cancer, 83, 1118-1127.
26. Wu,X. et al. (1998) Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J. Natl Cancer Inst., 90, 1393-1399.
27. Grossman,L. et al. (1999) DNA repair as a susceptibility factor in chromic diseases in human populations. In Disdaroglu,M. and Karakaya,A.E. (eds.) Advances in DNA Damage and Repair. Kluwer Academic/Plenum Publishers, New York, pp. 149-167.
28. Mullins,D.N. et al. (2005) CEBPG transcription factor correlates with antioxidant and DNA repair genes in normal bronchial epithelial cells but not in individuals with bronchogenic carcinoma. BMC Cancer 5, 141.
29. Zienolddiny,S. et al. (2006) Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis, 27, 560-567.
30. Jeon,H.S. et al. (2003) Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer. Carcinogenesis, 24, 1677-1681.
31. Shen,M. et al. (2005) Polymorphisms in the DNA nucleotide excision repair genes and lung cancer risk in Xuan Wei, China. Int. J. Cancer 116, 768-773.
32. Caporaso,N.E. (2002) Why have we failed to find the low penetrance genetic constituents of common cancers? Cancer Epidemiol. Biomarkers Prev., 11, 1544-1549.
33. Mohrenweiser,H. (2007) Survey of polymorphic sequence variation in the immediate 5′ region of human DNA repair genes. Mutat. Res., 616, 221-226.
34. Wacholder,S. et al. (2004) Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J. Natl Cancer Inst., 96, 434-442.
35. Ioannidis,J.P. et al. (2006) Concordance of functional in vitro data and epidemiological associations in complex disease genetics. Genet Med., 8, 583-593.
36. Hemminki,K. et al. (2000) Dna adducts, mutations, and cancer 2000. Regul. Toxicol. Pharmacol., 32, 264-275.
37. Cirulli,E.T. et al. (2007) In vitro assays fail to predict in vivo effects of regulatory polymorphisms. Hum. Mol. Genet. 16(16), 1931-1939.
38. Lesnick,T.G. et al. (2007) A genomic pathway approach to a complex disease: Axon guidance and Parkinson disease. PLoS Genet., 3 e98.
39. Hao,B. et al. (2006) A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene, 25, 3613-3620.
40. Carroll,S.B. (2005) Evolution at two levels: On genes and form. PLoS Biol., 3, e245.
41. King,M.C. et al. (1975) Evolution at two levels in humans and chimpanzees. Science, 188, 107-116.
42. Willey,J.C. et al. (2004) Standardized RT-PCR and the standardized expression measurement center. Methods Mol. Biol., 258, 13-41.
43. Canales,R.D. et al. (2006) Evaluation of DNA microarray results with quantitative gene expression platforms. Nat. Biotechnol., 24, 1115-1122.
44. Higuchi,R. et al. (1988) A general method of in vitro preparation and specific mutagenesis of DNA fragments: Study of protein and DNA interactions. Nucleic Acids Res., 16, 7351-7367.
45. Celi,F.S. et al. (1993) A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Res., 21 1047.
46. Ikeda,M.A. et al. (1993) Identification of distinct roles for separate E1A domains in disruption of E2F complexes. Mol. Cell. Biol. 13, 7029-7035.
47. Ye,J. et al. (1994) Identification of a DNA binding site for the nuclear factor YY1 in the human GM-CSF core promoter. Nucleic Acids Res., 22, 5672-5678.
48. Abramoff,M.D. et al. (2004) Image processing with image. J. Bipphotonics Intl, 11, 36-42.
49. Cartharius,K. et al. (2005) MatInspector and beyond: Promoter analysis based on transcription factor binding sites. Bioinformatics 21, 2933-2942.
50. Vinson,C. et al. (2006) Deciphering B-ZIP transcription factor interactions in vitro and in vivo. Biochim. Biophys. Acta, 1759, 4-12.
51. Cooper,C. et al. (1995) Ig/EBP (C/EBP gamma) is a transdominant negative inhibitor of C/EBP family transcriptional activators. Nucleic Acids Res., 23, 4371-4377.
52. Gao,H. et al. (2002) C/EBP gamma has a stimulatory role on the IL-6 and EL-8 promoters. J. Biol. Chem., 277, 38827-38837.
53. Johnson,P.F. et al. (1994) CCAAT/enhancer binding (C/EBP) proteins. In Tronch,F.,Yaniv,M, and Austin,R.G. (eds.) Liver Gene Expression. Landes Company, Austin, TX, pp. 231-258.
54. Hanlon,M. et al. (2000) C/EBP beta and Elk-1 synergistically transactivate the c-fos serum response element. BMC Cell Biol., 1, 2.
55. Jacob,K.K. et al. (2001) Elk-1, C/EBP alpha, and Pit-1 confer an insulin-responsive phenotype on prolactin promoter expression in Chinese hamster ovary cells and define the factors required for insulin-increaged transcription. J. Biol. Chem., 276, 24931-24936.
56. Takeshita,F. et al. (2004) Transcriptional regulation of the human TLR9 gene. J. Immunol., 173, 2552-2561.
57. Shimokawa,T. et al. (2003) C/EBP alpha and Ets protein family members regulate the human myeloid IgA Fc receptor (Fc alpha R, CD89) promoter. J. Immunol., 170, 2564-2572.
58. Lin,L. et al. (2005) Arsenite induces a cell stress-response gene, RTP801, through reactive oxygen species and transcription factors Elk-1 and CCAAT/enhancer-binding protein. Biochem. J., 392, 93-102.
59. Ren,B. et al. (2002) E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev., 16 245-256.
60. Polager,S. et al. (2002) E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene, 21, 437-446.
61. Huang,Y. et al. (1997) Role for E2F in DNA damage-induced entry of cells into S phase. Cancer Res., 57, 3640-3643.
62. Hofferer,M. et al. (1999) Increased levels of E2F-1-dependent DNA binding activity after UV- or gamma-irradiation. Nucleic Acids Res. 27, 491-495.
63. Blattner,C. et al. (1999) Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol., 19, 3704-3713.
64. Lin,W.C. et al. (2001) Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev., 15, 1833-1844.
65. Stevens,C. et al. (2003) Chk2 activates E2F-1 in response to DNA damage. Nat. Cell. Biol., 5, 401-409.
66. Berton,T.R. et al. (2005) Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation. Oncogene 24, 2449-2460.
67. Pediconi,N. et al. (2003) Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat. Cell Biol., 5, 552-558.
68. van Ginkel,P.R. et al. (1997) E2F-mediated growth regulation requires transcription factor cooperation. J. Biol. Chem., 272 18367-18374.
69. Schlisio,S. et al. (2002) Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J., 21, 5775-5786.